Log in to search using one of your social media accounts:

 

Onalespib could be an effective treatment for glioblastoma, preclinical studies show
This study showed that the targeted drug onalespib reduced the expression of cell-survival proteins such as AKT and endothelial growth factor receptor in glioma cell lines and glioma stem cells from patient tumors. This, in turn, reduced the survival, proliferation, invasion and migration of the cells. In animal models of glioblastoma the agent crossed the blood-brain barrier and showed effectiveness as a single agent and greater effectiveness in combination with temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2017 Category: International Medicine & Public Health Source Type: news

Temodar (Temozolomide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 25, 2017 Category: Drugs & Pharmacology Source Type: news

ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients
Novocure (NSDQ:NVCR) touted data today from the Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-diagnosed glioblastoma. The analyses were presented at the American Society for Radiation Oncology’s 2017 annual meeting in San Diego. Get the full story at our sister site, Drug Delivery Business News. The post ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Zika virus may be useful in treating brain tumours
Conclusion This is an interesting piece of research that shows how knowledge in one field of medicine can sometimes be applied to another field with surprising results. But it's important to be realistic about the stage of research. This is very much a "proof of concept" study, and tests on cells, tissues and mice don't necessarily translate into a safe and effective treatment for humans. The study has several limitations, but the fact the treatment so far hasn't been tested on humans is the most important. For one thing, Zika virus doesn't naturally infect mice, so researchers had to use a specially engineered v...
Source: NHS News Feed - September 6, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Novocure brings Optune tech to drug trial for glioblastoma
Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Get the full story at our sister site, Drug Delivery Business News. The post Novocure brings Optune tech to drug trial for glioblastoma appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 24, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Pharmaceuticals Wall Street Beat Celgene NovoCure Source Type: news

Peptide Vaccine Shows Clinical Benefit in Glioblastoma
A personalized peptide vaccination shows clinical benefit for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Brain Tumors News Source Type: news

Novocure touts quality of life data for Optune, chemo combo
Novocure (NSDQ:NVCR) touted health-related quality of life analyses from a pivotal Phase III trial combining its Optune device with standard temozolomide chemotherapy for patients with newly diagnosed glioblastoma. The data showed that adding Optune to temozolomide did not negatively impact health-related quality of life, except for itchy skin which the company attributed to skin irritation beneath Optune’s transducer arrays. The combination therapy improved deterioration-free survival of several predefined health-related quality of life scales compared to chemo alone, Novocure reported. Get the full story at our sis...
Source: Mass Device - May 8, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

NovoCure launches 2 pediatric trials of TTFields
NovoCure (NSDQ:NVCR) said today it is launching 2 pilot trials exploring the use of tumor treating fields to treat pediatric patients with high grade gliomas. The St. Helier, N.J.-based company produces the Optune, a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death. The 1st trial is being sponsored by the Pediatric Brain Tumor Consortium in collaboration with the National Cancer Institute and will study the feasibility of using TTFields on children w...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news

NovoCure shares rise on Q1 EPS beat
Shares in NovoCure (NSDQ:NVCR) rose today after the medical device maker beat losses per share expectations on Wall Street with its 1st quarter earnings results. The St. Helier, Jersey-based company posted losses of $18 million, or 21¢ per share, on sales of $34.9 million for the 3 months ended March 31, seeing bottom-line losses shrink 49.1% while sales grew a massive 167.2% compared with the same period in 2016. Losses per share were ahead of the 24¢ consensus on The Street, while sales fell just short of expectations of $37 million. “Our growth continued in the 1st quarter 2017. It was the ninth con...
Source: Mass Device - April 27, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
This piece of research has led to a Practice Changing Update on DynaMed Plus. It concludes that in elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 20, 2017 Category: Consumer Health News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Star Trek tricorder: This may be the best we can do – for now They don’t diagnose diseases with a few waves of the hand, the way that Dr. Leonard McCoy would with his tricorder on Star Trek. But 2 mobile platforms &n...
Source: Mass Device - April 17, 2017 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 5 Source Type: news

Novocure gains on additional Optune data
Shares in Novocure (NSDQ:NVCR) are on the rise again after the company today cited additional data from a pivotal trial evaluating its Optune device with temozolomide chemotherapy as a treatment for newly-diagnosed glioblastoma. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication. Get the full story on our sister site, Drug Delivery Business News. The post Novocure gains on additional Optune data appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 17, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Oncology Radiosurgery Wall Street Beat NovoCure Source Type: news

Vaccine/Chemotherapy Combination Improves Survival in Glioblastoma
Cytomegalovirus targeted vaccination plus high-dose chemotherapy with temozolomide can lead to long-term progression-free and overall survival in patients with newly diagnosed glioblastoma. (Source: CancerNetwork)
Source: CancerNetwork - April 16, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Brain Tumors News Source Type: news

Glioblastoma patients may benefit from a vaccine-chemotherapy combination
(American Association for Cancer Research) A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 14, 2017 Category: Global & Universal Source Type: news

AACR: TTFields + Temozolomide Ups Survival in Glioblastoma
Compliance with TTFields treatment predicts outcome, with better outcome for>18 hour/day (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 3, 2017 Category: Cancer & Oncology Tags: Neurology, Oncology, Conference News, Source Type: news

Novocure touts long-term data for Optune, chemo combination therapy for glioblastoma
Shares in Novocure (NSDQ:NVCR) jumped nearly 50% today after the company touted 5-year data today from the Phase III pivotal EF-14 trial evaluating its Optune device with temozolomide chemotherapy for the treatment of newly-diagnosed glioblastoma. Data from 695 patients show a consistent and maintained improvement in overall survival at 2, 3, 4 and 5 years, the St. Helier, N.J.-based company said. Novocure’s Optune mobile device delivers low-intensity, intermediate frequency, alternating electric fields, called “tumor treating fields” or TTFields, to inhibit cancer cell replication Get the full story at o...
Source: Mass Device - April 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Oncology Wall Street Beat NovoCure Source Type: news

Adding Temozolomide to Short-Course RT Effective in Elderly Glioblastoma
Elderly patients with glioblastoma had longer survival when temozolomide was added to short-course radiotherapy compared with undergoing short-course radiotherapy alone. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Brain Tumors News Radiation Oncology Source Type: news

Chemoradiation Boosts Survival in Elderly Glioblastoma Patients Chemoradiation Boosts Survival in Elderly Glioblastoma Patients
Adding temozolomide to radiotherapy improves survival in elderly glioblastoma patients when compared to radiotherapy alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Glioblastoma clinical trial shows combined therapy extends life for patients 65 and older
(University Health Network) Treating older patients who have malignant brain cancer with the chemotherapy drug temozolomide plus a short course of radiation therapy extends survival by two months compared to treating with radiation alone, show clinical trial results published in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 15, 2017 Category: Cancer & Oncology Source Type: news

A new prognostic classification may help clinical decision-making in glioblastoma
(Ohio State University Wexner Medical Center) New research shows that taking molecular variables into account will improve the prognostic classification of the lethal brain cancer called glioblastoma (GBM). Published in the journal JAMA Oncology, the study found that adding significant molecular biomarkers to the existing GBM classification system improves the prognostic classification of GBM patients who have been treated with radiation and the drug temozolomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 18, 2017 Category: Cancer & Oncology Source Type: news

NovoCure touts long-term analysis for Optune TTF, drug combo in brain cancer
NovoCure (NSDQ:NVCR) today released long-term analysis data from the phase 3 pivotal EF-14 trial of its Optune device in combination with temozolomide for treating newly diagnosed glioblastoma, touting superior survival results. Data from the trial indicated superior 2, 3 and 4-year survival rates for patients treated with the combined therapy over temozolomide alone. Data from the study is slated to be presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology in Scottsdale, Ariz. this week. “The long-term analysis further supports our data showing that Optune together with temozolomide i...
Source: Mass Device - November 18, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Oncology NovoCure Source Type: news

Ibudilast Plus Temozolomide Shows Preclinical Promise in Glioblastoma
The anti-inflammatory ibudilast shows early preclinical promise against glioblastoma cell lines when combined with temozolomide, according to research presented at the 2016 SNO Scientific Meeting. (Source: CancerNetwork)
Source: CancerNetwork - November 18, 2016 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Brain Tumors News Conferences/SNO 2016 Source Type: news

Novocure touts long-term analysis of Optune drug-device combo
Novocure (NSDQ: NVCR) touted a long-term analysis of data from a Phase III pivotal trial of its Optune device in combination with temozolomide for the treatment of newly-formed glioblastomas. Survival data for nearly 700 patients confirmed interim results from the trial, 1st published in December 2015 in the Journal of the American Medical Assn. Patients treated with Optune plus temozolomide had superior 2-, 3- and 4-year survival rates compared to patients treated with temozolomide alone. The results come weeks after the St. Helier, N.J.-based company announced that Optune, in combination with placlitaxel, is effecti...
Source: Mass Device - September 12, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Radiosurgery NovoCure Source Type: news

DelMar, Accurexa ink deal for chemotherapy combo
DelMar Pharmaceuticals and Accurexa  said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer. The agreement calls for DelMar to supply the drug dianhydrogalactitol (VAL-083) as part of a combination with another chemotherapeutic, either temozolomide or carmustine, for local delivery to the tumor via Accurexa’s ACX-31 implantable polymer wafer. DelMar said its drug proved successful in more than 40 clinical trials sponsored by the U.S. National Cancer Institute, winning orphan drug designation as a treatment for gliomas, medulloblastoma and ovarian c...
Source: Mass Device - September 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Oncology Pharmaceuticals Research & Development Accurexa Inc. DelMar Pharmaceuticals Source Type: news

New Standard for Older Patients With Glioblastoma
(MedPage Today) -- Radiation plus temozolomide extends survival (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 10, 2016 Category: Geriatrics Source Type: news

Temozolomide + RT boosts survival in elderly with glioblastoma
CHICAGO – Adding concomitant and adjuvant temozolomide to a shorter course of radiotherapy (RT) for elderly patients with glioblastoma improves progression-free survival, according to a phase III... (Source: Clinical Neurology News)
Source: Clinical Neurology News - June 10, 2016 Category: Neurology Source Type: news

Age Not an Issue: Chemo Also for Elderly GlioblastomaAge Not an Issue: Chemo Also for Elderly Glioblastoma
The first trial specifically in elderly patients with glioblastoma, most of whom were over 70, shows that temozolomide plus radiation improves survival also in this patient population. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

'Huge' Survival Benefit, New Standard of Care in Glioma'Huge' Survival Benefit, New Standard of Care in Glioma
Adding adjuvant temozolomide to radiotherapy for patients with grade 3 anaplastic glioma without the 1p/19 deletion is a new standard of care. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 5, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A new frontier in the war on brain cancer with NovoCure chairman Bill Doyle
Novocure, the St. Helier, Jersey-based medical device company, which raised more than $158M in an IPO last year, is trying to change the way we fight cancer. Company officials say its proprietary Tumor Treating Fields technology, marketed under the product name Optune, are a new tool in the war against cancer. Currently, the company has FDA approval for Glioblastoma, the deadliest form of brain cancer. The results thus far have been impressive for Novocure. In December, data from the company’s pivotal phase 3 trial of its Optune device, published in the Journal of the American Medical Association, showed ...
Source: Mass Device - April 26, 2016 Category: Medical Equipment Authors: Brian Johnson Tags: Device Talks Podcasts NovoCure Source Type: news

Novocure wins reimbursement from Humana for Optune brain cancer device
NovoCure (NSDQ:NVCR) said today it won reimbursement from Humana for treatments with its Optune device for patients with recurrent glioblastoma. The Optune is a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields,” to inhibit cancer cell replication and cause cancer cell death. The new reimbursement win brings the number of commercial payers covering Optune treatment up to 9, NovoCure said in a press release. In January, NovoCure said  it applied for a supplemental pre-market approval from the FDA for the 2nd generation ...
Source: Mass Device - March 3, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Oncology NovoCure Source Type: news

Lannett Receives FDA Approval For Temozolomide Capsules
PHILADELPHIA, Feb. 11, 2016 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (LCI) today announced that its wholly owned subsidiary, Kremers Urban Pharmaceuticals Inc. (KU), has received approval from the U.S. Food and Drug Administratio... Biopharmaceuticals, Generics, FDALannett Company, Kremers Urban Pharmaceuticals, Temozolomide, Temodar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2016 Category: Pharmaceuticals Source Type: news

New Mesothelioma Clinical Trial Hopes to Improve Chemotherapy
This study is part of a broad development program that includes a number of additional planned studies." TRACON Pharmaceuticals develops novel targeted cancer therapies. Its TRC105 antibody is directed at renal cell carcinoma and hepatocellular carcinoma. This clinical trial with TRC102 is one of five nationally involving methoxyamine, but one of more than 200 trials for mesothelioma. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - January 27, 2016 Category: Environmental Health Authors: Tim Povtak Tags: Research & Clinical Trials Source Type: news

NovoCure touts JAMA publication of Optune trial data
NovoCure (NSDQ:NVCR) said today data from the pivotal phase 3 trial of its Optune device, in combination with standard-of-care temozolomide, for treating newly diagnosed glioblastoma has been published in the Journal of the American Medical Association. The results from the EF-14 trial reported that Optune along with temozolomide significantly extended progression-free survival and overall survival compared to temozolomide alone in treating newly diagnosed glioblastoma. “The EF-14 data are spectacular. They support Tumor Treating Fields as a new standard of care for patients suffering from glioblastoma. These re...
Source: Mass Device - December 15, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Oncology Clinical Trials NovoCure Source Type: news

Tumor-Treating Fields Up Survival in GlioblastomaTumor-Treating Fields Up Survival in Glioblastoma
In the treatment of glioblastoma, electromagnetic field therapy with temozolomide improves progression-field survival and median overall survival. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medtech approvals: FDA releases October 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in October 2015: Summary of PMA Originals & Supplements Approved Originals: 9 Supplements: 133 Summary of PMA Originals Under Review Total Under Review: 58 Total Active: 32 Total On Hold: 26 Summary of PMA Supplements Under Review Total Under Review: 597 Total Active: 433 Total On Hold: 164 Summary of All PMA Submissions Originals: 7 Supplements: 74 Summary of PMA Supplement PMA Approval/Denial Decision Times Number of Approvals: 133 Number of Denials: 0 Average Days Fr Receipt to Decision (Total Time): 161.5 FDA Ti...
Source: Mass Device - December 4, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

NovoCure’s cancer therapy effective in late-stage study
(Reuters) – NovoCure (NSDQ:NVCR) said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23% in extended trading. NovoCure’s therapy, Optune, which was evaluated in combination with Roche Holding AG’s cancer drug, reduced the risk of death by 39% in patients, compared with patients treated with Avastin alone, Novocure said in a statement on Friday. Optune is an FDA-approved device for use in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain tumor in which 90% of adult ...
Source: Mass Device - November 20, 2015 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Clinical Trials NovoCure Source Type: news

NovoCure wins expanded indications for Optune brain tumor-zapping device
NovoCure said it won expanded indications from the FDA and a new CE Mark indication in the European Union for its brain-tumor treating Optune device. The Optune device uses NovoCure’s “tumor treating fields,” which use low-intensity, intermediate-frequency alternating electric fields that limit cancer cell replication and kill cancer cells, the St. Helier, N.J.-based company said. The FDA granted NovoCure clearance for its Optune in combination with prescribed temozolomide for the treatment of adult patients with newly diagnosed glioblastomas. “Novocure is committed to helping patients with glioblas...
Source: Mass Device - October 6, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Oncology Radiosurgery Regulatory/Compliance NovoCure Source Type: news

FDA Approves Optune In Combination With Temozolomide For The Treatment Of Newly Diagnosed Glioblastoma
Novocure has announcedthat the FDAhas approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed glioblastoma (GBM). Optune is a portable, non-invasive device that delivers low-intensity, intermediate frequency, alternating electric fields – referred to as Tumor Treating Fields (TTFields) – that inhibit cancer cell replication and cause cancer cell death. (Source: Medical Design Online News)
Source: Medical Design Online News - October 6, 2015 Category: Medical Equipment Source Type: news

FDA approves expanded indication for medical device to treat a form of brain cancer
The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. It is given along with the chemotherapy drug temozolomide (TMZ) following standard treatments that include surgery, chemotherapy, and radiation therapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 5, 2015 Category: American Health Source Type: news

Cancer treatment outcomes are influenced by genetics and race, according to new study
A person's response to anticancer drug treatments is strongly related to their genetic ancestry, new research concludes. Notable associations were found for the drug temozolomide, which is used to treat brain tumors. Other drugs with results that suggest an association include etoposide and mitomycin, but the authors note that these results should be viewed as hypothesis generation. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 11, 2015 Category: Science Source Type: news

Merck Recalls Chemo Drug Over Packaging Issue
Merck is recalling 276,000 bottles of branded chemotherapy drug, Temodar and generic drug, temozolomide, due to cracked child-proof caps. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 19, 2015 Category: Pharmaceuticals Source Type: news

Temodar Bottles Recalled Due to Cracks in Kid-Proof CapsTemodar Bottles Recalled Due to Cracks in Kid-Proof Caps
Consumers are to immediately inspect bottles of Temodar capsules and generic temozolomide capsules for cracked caps; the company is recalling all bottles found to have cracked caps. News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement
Dateline City: KENILWORTH, N.J. Patients Should Visually Examine Bottle Caps for Cracks and if Cracks are Found, Ensure the Bottles are Stored Out of the Reach of Children Replacement Caps for Patients Are Available Medication Within the Bottles Is Not Affected; Patients May Continue to Take Their Medicine as Prescribed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, in conjunction with the U.S. Consumer Product Safety Commission (CPSC) today asked that all customers...
Source: Merck.com - Product News - August 18, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News Source Type: news

MD Anderson study shows why some brain cancers resist treatment
(University of Texas M. D. Anderson Cancer Center) Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 2, 2015 Category: Cancer & Oncology Source Type: news

MD Anderson Study Shows Why Some Brain Cancers Resist Treatment
Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - March 2, 2015 Category: Cancer & Oncology Source Type: news

No Benefit from Dose-Dense Chemo in Glioblastoma
(MedPage Today) -- Intensified chemoradiation with temozolomide for newly diagnosed glioblastoma failed to improve survival or slow disease progression, according to results of a randomized trial. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - October 13, 2013 Category: Psychiatry Source Type: news

Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo
Glioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide. Thus, novel therapeutic strategies must to be investigated for the development of a more effective treatment strategy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 13, 2013 Category: Consumer Health News Tags: Stem Cell Research Source Type: news

Migration capacity of human umbilical cord mesenchymal stem cells towards glioma in vivo
(Neural Regeneration Research) Glioblastoma is the most common malignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 10, 2013 Category: Global & Universal Source Type: news

Researchers Aiming To Suppress Therapy Resistance In Brain Cancer
Gliomas are malignant brain tumors that arise from glial cells called astrocytes, found in the central nervous system. "In treating malignant gliomas, we currently combine radiotherapy with the anticancer drug temozolomide. However, in some patients, tumors rapidly become resistant to both treatment methods," says neurooncologist Professor Dr. Michael Platten, who leads a cooperation unit of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Department of Neurooncology of Heidelberg University Hospital... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 29, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Virus Combination Effective Against Deadly Brain Tumor, Moffitt Cancer Center Study Shows
A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research. Peter A. Forsyth, M.D., of Moffitt's Neuro-Oncology Program, says the combination has been shown to infect and kill both brain cancer stem cells and differentiated compartments of glioblastoma multiforme. The finding means that barriers to treating the disease, such as resistance to the drug temozolomide, may be overcome... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 24, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news